Cargando…

Safety and Effectiveness of Etanercept Biosimilar SB4 for Rheumatic Diseases in South Korea: Real-World Post-marketing Surveillance Data

INTRODUCTION: SB4 is the first approved biosimilar of etanercept, a biologic tumor necrosis factor inhibitor, to treat various autoimmune diseases including axial spondylarthritis (axSpA), rheumatoid arthritis (RA), psoriatic arthritis (PsA), and plaque psoriasis (PsO). This post-marketing surveilla...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoo, Wan-Hee, Kang, Young Mo, Kim, Dong Wook, Kang, Eun Ha, Lee, Yeon-Ah, Suh, Chang-Hee, Sung, Yoon-Kyoung, Lee, Sang-Hoon, Gu, Dong-Ha, Lee, Jiwon, Choe, Jung-Yoon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011358/ https://www.ncbi.nlm.nih.gov/pubmed/36482248 http://dx.doi.org/10.1007/s40744-022-00515-z

Ejemplares similares

Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars
por: Ebbers, Hans C., et al.
Publicado: (2020)

Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept
por: Cho, Ick Hyun, et al.
Publicado: (2016)

Etanercept biosimilars
por: Azevedo, Valderilio F., et al.
Publicado: (2014)

Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review
por: Ebbers, Hans C., et al.
Publicado: (2019)

Effectiveness and safety of a biosimilar-to-biosimilar switch of the TNF inhibitor etanercept in patients with chronic inflammatory rheumatic diseases
por: Kiltz, Uta, et al.
Publicado: (2022)

Safety and Effectiveness of SB2 (Infliximab Biosimilar) in Adult Patients with Immune-Mediated Inflammatory Diseases: A Post-Marketing Surveillance in Korea
por: Kim, Dong W., et al.
Publicado: (2023)

Consistency of Product Quality for SB5, an Adalimumab Biosimilar
por: Lee, JongAh Joanne, et al.
Publicado: (2023)

GP2015: An Etanercept Biosimilar
por: Deeks, Emma D.
Publicado: (2017)

Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany
por: Moorkens, Evelien, et al.
Publicado: (2020)

Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study
por: Park, Min-Chan, et al.
Publicado: (2019)

A randomized phase l pharmacokinetic study comparing SB4 and etanercept reference product (Enbrel®) in healthy subjects
por: Lee, Yoon Jung, et al.
Publicado: (2016)

Focus on biosimilar etanercept – bioequivalence and interchangeability
por: Cantini, Fabrizio, et al.
Publicado: (2018)

Correction to: GP2015: An Etanercept Biosimilar
por: Deeks, Emma D.
Publicado: (2018)

Observational study of inflammatory arthritis treatment by etanercept originator switched to an etanercept biosimilar
por: Felis-Giemza, Anna, et al.
Publicado: (2019)

Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator Etanercept
por: Meijboom, Rosanne W., et al.
Publicado: (2021)

Assessment of the Molecular Mechanism of Action of SB3, a Trastuzumab Biosimilar
por: Paek, Kyungyeol, et al.
Publicado: (2019)

Efficacy and Drug Survival after Switching from Etanercept to the Biosimilar SB4: A Real-Life Long-Term Study
por: Parisi, Simone, et al.
Publicado: (2022)

Factors for starting biosimilar TNF inhibitors in patients with rheumatic diseases in the real world
por: Sung, Yoon-Kyoung, et al.
Publicado: (2020)

Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis
por: Chadwick, Laura, et al.
Publicado: (2018)

Physicochemical Characterization of Altebrel™, a Proposed Etanercept Biosimilar
por: Fazel, Ramin, et al.
Publicado: (2019)

SB8: A Bevacizumab Biosimilar
por: Syed, Yahiya Y.
Publicado: (2020)

Uptake of Biosimilars and Its Economic Implication for the Treatment of Patients with Rheumatoid Arthritis in Korea
por: Cho, Soo-Kyung, et al.
Publicado: (2021)

Physicochemical and biological characterization of SB2, a biosimilar of Remicade® (infliximab)
por: Hong, Juyong, et al.
Publicado: (2016)

Adenoviral Pneumonia During Etanercept Treatment in a Patient with Rheumatoid Arthritis
por: Kang, Min-Jung, et al.
Publicado: (2007)

Cancer Incidence Among Air Transportation Industry Workers Using the National Cohort Study of Korea
por: Lee, Wanhyung, et al.
Publicado: (2019)

Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis
por: Ditto, Maria Chiara, et al.
Publicado: (2020)

Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study
por: Smolen, Josef S, et al.
Publicado: (2018)

Correction to: SB8: A Bevacizumab Biosimilar
por: Syed, Yahiya Y.
Publicado: (2020)

Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial
por: Pivot, Xavier, et al.
Publicado: (2023)

Biological Characterization of SB3, a Trastuzumab Biosimilar, and the Influence of Changes in Reference Product Characteristics on the Similarity Assessment
por: Lee, Jae Hee, et al.
Publicado: (2019)

Predicting Loss of Efficacy after Non-Medical Switching: Correlation between Circulating TNF-α Levels and SB4 in Etanercept to SB4 Switchers and Naïve Patients with Rheumatic Disease
por: Benucci, Maurizio, et al.
Publicado: (2022)

Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the BSRBR-RA
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2023)

Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results
por: Smolen, Josef S., et al.
Publicado: (2017)

A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers
por: Shin, Donghoon, et al.
Publicado: (2020)

Autoantibody Biomarkers in Rheumatic Diseases
por: Kang, Eun Ha, et al.
Publicado: (2020)

Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2—Biosimilar and Originator Etanercept in the Outpatient Setting
por: Moorkens, Evelien, et al.
Publicado: (2019)

New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept
por: Miranda-Hernández, Mariana P., et al.
Publicado: (2016)

Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts
por: Derikx, Lauranne A A P, et al.
Publicado: (2021)

Evaluation of the Structural, Physicochemical, and Biological Characteristics of SB11, as Lucentis(®) (Ranibizumab) Biosimilar
por: Kim, Eunji, et al.
Publicado: (2022)

Association of serum free thyroxine and glucose homeostasis: Korea National Health and Nutrition Examination Survey
por: Ha, Jeonghoon, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_889cupdd62ceb6b2lrq1hj2e6k